Indian Journal of Pharmacology Home 

RESEARCH ARTICLE
[View FULLTEXT] [Download PDF]
Year : 2013  |  Volume : 45  |  Issue : 6  |  Page : 608--611

Parenteral polymyxins: Assessing efficacy and safety in critically ill patients with renal dysfunction

Kavita Sekhri1, Ruchika Nandha1, Amit Mandal2, Deepak Bhasin2, Harpal Singh2 
1 Department of Pharmacology, Dr. Harvansh Singh Judge Institute of Dental Sciences, Panjab University, Chandigarh, India
2 Department of Pulmonary medicine and Critical care, Medical Intensive Care Unit, Fortis Hospital, Mohali, Punjab, India

Correspondence Address:
Kavita Sekhri
Department of Pharmacology, Dr. Harvansh Singh Judge Institute of Dental Sciences, Panjab University, Chandigarh
India

Objectives: Studies have established the effectiveness and safety of polymyxins in treating multidrug resistant (MDR) pathogens. However, the challenge is whether these nephrotoxic drugs can be administered in compromised renal states. The present study was undertaken to establish their role in such patients. The effectiveness and nephrotoxicity of polymyxins in critically ill-patients harboring MDR Gram-negative bacteria with already compromised renal functions was compared with those with normal renal functions. Materials and Methods: This retrospective cohort study (March 2008-March 2010) was conducted in the intensive care unit of a tertiary care hospital. A total of 48 eligible critically ill-patients receiving polymyxins were enrolled. A comparison was carried out (length of stay in hospital, mortality, renal function) between patients with acute kidney injury (AKI, n = 18; defined by the RIFLE classification) and patients with normal renal function (non-AKI, n = 30). Results: Patients with baseline AKI had a significantly higher adjusted mortality rate at admission when compared with the non-AKI group. At the end of therapy with polymyxins, 26.66% non-AKI patients developed renal dysfunction while 38.88% of patients in the AKI group had worsening of renal function (P = 0.006). However, there was no significant difference in the length of hospital stay (23.9 ± 13.24 vs. 30.5 ± 22.50; P = 0.406) and overall mortality (44.4% vs. 36.7%; P = 0.76) between two groups. Conclusion: Polymyxins can be administered in AKI patients with favorable results provided used judiciously with strict monitoring of renal functions, dose modification according to creatinine clearance and aggressive fluid management.


How to cite this article:
Sekhri K, Nandha R, Mandal A, Bhasin D, Singh H. Parenteral polymyxins: Assessing efficacy and safety in critically ill patients with renal dysfunction.Indian J Pharmacol 2013;45:608-611


How to cite this URL:
Sekhri K, Nandha R, Mandal A, Bhasin D, Singh H. Parenteral polymyxins: Assessing efficacy and safety in critically ill patients with renal dysfunction. Indian J Pharmacol [serial online] 2013 [cited 2021 Jun 20 ];45:608-611
Available from: https://www.ijp-online.com/article.asp?issn=0253-7613;year=2013;volume=45;issue=6;spage=608;epage=611;aulast=Sekhri;type=0